sinc
first
case
human
infect
middl
east
respiratori
syndrom
coronaviru
merscov
saudi
arabia
june
case
confirm
merscov
infect
relat
death
report
sinc
octob
vast
major
case
report
saudi
arabia
epidem
spread
countri
ceas
year
later
unlik
sarscov
disappear
littl
less
year
emerg
due
high
fatal
rate
observ
merscov
infect
patient
much
effort
put
understand
origin
pathophysiolog
novel
coronaviru
prevent
becom
endem
human
review
focus
particular
origin
epidemiolog
clinic
manifest
merscov
well
diagnosi
treatment
infect
patient
experi
gain
recent
year
manag
differ
risk
relat
kind
epidem
key
prepar
futur
outbreak
communic
diseas
mot
maladi
merscov
coronaviru
pneumoni
r
u
depui
le
premier
ca
dinfect
au
middl
east
respiratori
syndrom
coronaviru
merscov
en
arabi
saoudit
en
juin
le
merscov
lieu
au
octobr
plu
de
ca
dinfect
et
la
grand
de
ca
ont
en
arabi
saoudit
mai
depui
pay
et
nest
toujour
pa
an
son
contrair
au
srascov
qui
disparu
un
peu
moin
de
deux
an
sa
en
raison
du
taux
import
de
parmi
le
patient
par
le
merscov
beaucoup
deffort
ont
pour
comprendr
lorigin
et
la
physiopathologi
de
ce
nouveau
coronaviru
ainsi
que
pour
lutter
contr
une
instal
de
ce
viru
au
sein
de
la
popul
humain
cett
revu
sattach
plu
retrac
lorigin
et
du
merscov
la
cliniqu
chez
le
patient
ainsi
que
la
prise
en
charg
diagnostiqu
et
de
patient
acquis
au
cour
de
dan
la
gestion
de
risqu
ce
type
est
important
pour
pouvoir
fair
face
la
prochain
dinfect
transmiss
first
case
infect
attribut
middl
east
respiratori
syndrom
coronaviru
merscov
detect
saudi
arabia
june
merscov
spread
sever
neighbor
countri
mainli
jordan
qatar
see
fig
import
case
diseas
report
throughout
world
asia
africa
europ
america
octob
con
first
two
coronavirus
demonstr
caus
respiratori
infect
human
coronavirus
identifi
held
respons
respiratori
infect
moder
sever
human
despit
virus
identifi
sever
report
caus
lower
respiratori
tract
infect
gener
accept
coronavirus
low
pathogen
emerg
sarscov
sever
acut
respiratori
syndrom
coronaviru
viru
fatal
rate
estim
sar
outbreak
result
case
final
contain
two
year
later
viru
detect
sinc
renew
interest
coronaviru
research
follow
sar
epidem
two
novel
endem
human
coronavirus
identifi
respect
could
replic
cell
cultur
new
virus
respons
respiratori
infect
moder
serious
like
coronavirus
great
effort
made
identifi
coronavirus
anim
popul
sar
outbreak
order
better
understand
control
risk
animaltohuman
transmiss
result
discoveri
coronavirus
numer
anim
speci
except
sheep
goat
fish
nonhuman
primat
first
case
merscov
infect
report
jeddah
saudi
arabia
june
patient
man
die
lung
kidney
failur
day
admit
hospit
shortli
afterward
septemb
second
patient
admit
hospit
unit
kingdom
sever
respiratori
infect
relat
novel
coronaviru
follow
travel
middl
east
new
viru
found
replic
tissu
cultur
model
rapidli
isol
identifi
case
retrospect
case
diseas
found
occur
aforement
case
april
outbreak
zarqa
hospit
jordan
affect
staff
intens
care
unit
two
fatal
case
respiratori
sampl
collect
later
confirm
posit
merscov
initi
case
rapidli
follow
seri
outbreak
saudi
arabian
provinc
character
infect
health
profession
direct
contact
patient
similar
outbreak
observ
sever
neighbor
countri
qatar
bahrain
kuwait
jordan
tunisia
health
author
react
quickli
report
epidem
strong
resembl
observ
clinic
featur
sarscov
infect
inde
although
patient
develop
mild
infect
fatal
rate
patient
infect
merscov
follow
identif
merscov
great
effort
put
find
anim
speci
origin
order
stop
spread
diseas
human
merscov
rapidli
determin
genotyp
close
relat
betacoronaviru
lineag
c
virus
identifi
bat
base
find
major
role
bat
genet
divers
spread
coronavirus
much
initi
work
aim
find
natur
reservoir
merscov
focus
bat
howev
conclus
evid
demonstr
bat
natur
reservoir
merscov
arabian
peninsula
found
despit
identif
close
relat
virus
bat
subsaharan
africa
far
exist
outbreak
strong
epidemiolog
link
identifi
human
case
camel
result
isol
camel
virus
directli
relat
merscov
could
replic
cultur
human
cell
investig
dromedari
camel
serum
collect
collect
earli
demonstr
viru
alreadi
widespread
seroposit
rate
east
african
countri
somalia
sudan
egypt
countri
export
dromedari
camel
arabian
countri
also
kenya
nigeria
tunisia
ethiopia
burkina
faso
morocco
phylogenet
analysi
reveal
distinct
coronaviru
lineag
dromedari
camel
includ
one
recombin
lineag
led
merscov
epidem
human
merscov
betacoronaviru
belong
lineag
c
envelop
viru
positivesens
singlestrand
rna
genom
kb
electron
microscopi
virion
gener
spheric
surfac
project
spike
form
surfac
protein
creat
imag
reminisc
crown
solar
corona
positivesens
singlestrand
rna
genom
act
messeng
rna
mrna
cap
polyadenyl
tail
play
three
role
host
cell
cycl
act
initi
rna
molecul
infect
cycl
ii
templat
replic
transcript
iii
substrat
packag
newli
assembl
viral
particl
merscov
genom
organ
way
coronaviru
speci
first
two
third
merscov
genom
contain
two
overlap
read
frame
translat
replicationtranscript
complex
includ
nonstructur
protein
remain
third
genom
encod
four
structur
protein
spike
envelop
e
membran
nucleocapsid
n
protein
well
five
accessori
protein
requir
genom
replic
probabl
involv
virul
flank
sequenc
end
genom
contain
untransl
region
utr
fig
viral
particl
enter
cell
two
way
probabl
contribut
broad
tissu
tropism
viru
replic
mainli
respiratori
epitheli
cell
also
infect
mani
cell
type
via
endosom
pathway
domain
merscov
spike
protein
bind
receptor
dipeptidyl
peptidas
induc
endocytosi
viral
particl
chang
conform
subunit
protein
mediat
virushost
membran
fusion
uncoat
viru
rna
merscov
also
enter
host
cell
via
nonendosom
mechan
direct
fusion
viru
plasma
membran
follow
protein
cleavag
human
proteas
follow
entri
cytoplasm
uncoat
viru
nucleocapsid
viral
genom
rna
translat
produc
two
polypeptid
form
replicasetranscriptas
complex
initi
replicasetranscriptas
complex
use
genom
rna
produc
nonstructur
protein
assembl
replic
complex
replic
complex
replic
genom
rna
produc
subgenom
rna
ensur
translat
structur
protein
virion
assembl
endoplasm
reticulum
membran
viral
protein
genom
rna
group
togeth
bud
lumen
endoplasm
reticulum
virion
export
via
secretori
pathway
endoplasm
reticulum
golgi
intermedi
compart
extracellular
environ
protein
drive
packag
process
select
organ
viral
envelop
compon
assembl
site
interact
nucleocapsid
allow
bud
sever
larg
serolog
studi
suggest
case
asymptomat
mild
merscov
infect
occur
regularli
although
infrequ
import
case
difficult
assess
therefor
difficult
determin
whether
case
due
take
part
humantohuman
transmiss
sever
studi
suggest
less
infect
patient
transmit
viru
individu
come
contact
even
begin
outbreak
diseas
therefor
seem
spread
due
frequent
animaltohuman
transmiss
camel
human
limit
subsequ
humantohuman
transmiss
unfortun
except
observ
local
outbreak
caus
humantohuman
transmiss
observ
regular
basi
mostli
hospit
date
poignant
exampl
outbreak
occur
south
korea
index
case
caus
secondari
case
among
care
provid
lead
fatal
outbreak
character
key
role
super
spreader
delay
diagnosi
high
doctor
shop
behavior
import
confin
space
wait
room
hospit
room
ambul
exampl
resembl
sarscov
spread
mechan
strike
despit
lower
degre
transmiss
care
provid
merscov
regular
case
importedm
recent
report
england
august
repres
real
threat
local
epidem
outsid
saudi
arabia
special
screen
isol
procedur
need
implement
unit
like
receiv
patient
suspect
merscov
infect
possibl
first
measur
taken
delay
departur
particular
individu
chronic
diseas
pregnant
women
children
measur
nevertheless
challeng
maintain
today
viru
still
present
year
apparit
prevent
measur
aim
prevent
animaltohuman
transmiss
humantohuman
transmiss
therefor
recommend
avoid
contact
domest
anim
firstli
dromedari
camel
secret
raw
milk
insuffici
cook
meat
also
advis
avoid
eat
fruit
veget
might
contact
anim
secret
wash
peel
oneself
avoid
humantohuman
transmiss
usual
recommend
prevent
spread
respiratori
viru
appli
hand
wash
soapi
water
alcoholbas
solut
cover
one
nose
mouth
sneez
refrain
shake
hand
touch
one
mouth
nose
one
hand
avoid
contact
peopl
respiratori
symptom
final
last
seri
recommend
focu
behav
case
suspici
symptom
consult
doctor
soon
symptom
occur
travel
delay
return
symptom
disappear
ii
symptom
occur
day
return
home
consult
doctor
tell
himher
recent
travel
pcrbase
detect
method
current
prefer
option
detect
viru
respiratori
sampl
make
diagnosi
merscov
infect
serolog
test
also
perform
often
use
secondlin
diagnost
investig
patient
high
suspicion
merscov
neg
result
direct
pcr
test
variou
respiratori
matric
use
nasopharyng
swab
nasopharyng
tracheal
aspir
bronchoalveolar
lavag
bal
even
case
induc
sputum
deepest
sampl
tracheal
aspir
bal
show
greatest
sensit
significantli
higher
viral
load
genom
amplif
detect
method
use
pcr
initi
mostli
develop
situ
perform
biosafeti
level
refer
facil
time
result
gener
rel
long
h
due
usual
time
requir
convent
pcr
test
must
ad
addit
prepar
sampl
neutral
time
need
protect
laboratori
staff
viru
pcr
method
use
gener
semiquantit
studi
suggest
correl
amount
viru
detect
sever
symptom
nevertheless
consensu
reach
yet
regard
threshold
level
could
actual
predict
clinic
sever
target
envelop
gene
upe
recommend
confirmatori
test
orf
n
gene
result
diverg
sequenc
sometim
requir
obtain
conclus
result
today
increas
number
commerci
test
becom
avail
altona
diagnost
fast
track
diagnost
primerdes
ltd
even
time
result
less
hour
test
pointofcar
perform
facil
standard
laboratori
follow
sampl
neutral
facil
commerci
test
must
alway
valid
use
check
sensit
compar
perform
refer
method
acut
viral
infect
antibodi
gener
detect
day
onset
symptom
patient
especi
sever
infect
time
interv
antibodi
detect
may
even
longer
serolog
test
therefor
littl
help
initi
diagnosi
symptomat
patient
use
epidemiolog
investig
highli
immunogen
n
viral
protein
wide
use
target
serolog
test
found
coronavirus
variou
approach
develop
serum
neutral
assay
microarray
recent
elisa
confirm
microneutr
test
method
technic
complex
requir
high
level
expertis
restrict
use
highli
special
facil
first
case
infect
merscov
report
hospitalacquir
merscov
infect
describ
worldwid
repres
third
case
report
saudi
arabia
earli
stage
epidem
cluster
hospitalacquir
infect
frequent
observ
first
outbreak
probabl
contribut
spread
diseas
primari
site
viru
infect
whole
arabian
peninsula
strike
exampl
hospitalacquir
outbreak
korean
outbreak
care
provid
often
affect
repres
case
case
describ
middl
east
countri
particular
saudi
arabia
predomin
male
patient
variou
studi
mean
patient
age
rang
year
comorbid
found
patient
particular
diabet
high
blood
pressur
follow
heart
condit
final
obes
mean
incub
time
day
gener
interv
time
onset
symptom
first
case
second
case
day
ident
respiratori
syncyti
viru
rsv
threefold
influenza
viru
main
challeng
merscov
infect
absenc
specif
clinic
featur
differenti
diagnosi
viral
respiratori
diseas
difficulti
combin
precautionari
action
taken
avoid
potenti
secondari
contamin
merscov
result
medic
confus
inappropri
patient
manag
due
prolong
difficult
isol
make
imposs
perform
necessari
complementari
test
wait
pcr
result
clinic
featur
merscov
infect
extrem
variabl
rang
absenc
symptom
case
flulik
syndrom
pneumonia
acut
respiratori
distress
syndrom
ard
three
frequent
symptom
fever
iqr
cough
dyspnea
mani
secondari
symptom
report
sputum
product
odynophagia
digest
system
sign
hemoptysi
myalgia
headach
diarrhea
significantli
frequent
patient
infect
merscov
patient
anoth
acut
febril
respiratori
condit
sever
mer
character
predominantli
ard
acut
kidney
failur
sever
case
multipl
organ
failur
fatal
one
third
patient
develop
pneumonia
develop
ard
median
time
respiratori
failur
day
onset
symptom
depend
studi
hospit
patient
admit
intens
care
unit
icu
sinc
first
mer
outbreak
document
octob
case
merscov
infect
confirm
laboratori
test
relat
death
differ
countri
retrospect
fatal
rate
vari
outbreak
rang
mortal
rate
observ
korean
outbreak
probabl
reliabl
epidemiolog
due
comprehens
investig
carri
death
rate
highest
among
patient
admit
icu
rang
cohort
studi
perform
saudi
arabia
fatal
rate
merscov
patient
howev
patient
cohort
younger
less
symptom
show
less
radiolog
featur
admit
icu
find
latter
studi
diverg
therefor
situat
observ
hospit
perhap
better
reflect
infect
profil
gener
popul
younger
subject
less
symptomat
therefor
less
frequent
admit
hospit
time
interv
onset
symptom
death
rang
day
final
coinfect
respiratori
virus
particular
influenza
describ
although
impact
combin
infect
evalu
coinfect
bacteria
also
report
patient
develop
sever
diseas
specif
laboratori
find
relat
merscov
infect
nevertheless
patient
acut
respiratori
infect
mersendem
area
merscov
infect
associ
normal
leukocyt
andor
polymorphonuclear
neutrophil
count
elev
transaminas
moreov
hyperleukocytosi
lymphocytopenia
thrombocytopenia
hypoalbuminemia
elev
serum
creatinin
ldh
crp
level
hypoxemia
repeat
report
merscov
infect
patient
associ
sever
death
imag
chest
xray
sometim
chest
ct
reveal
infectionrel
featur
case
lesion
observ
unior
multifoc
ground
glass
opacif
subpleur
lower
lobe
predomin
sometim
bilater
bibas
involv
featur
organ
pneumonia
mortal
highest
elderli
male
patient
comorbid
especi
diabet
patient
saudi
arabia
middl
east
increas
mortal
rate
compar
patient
korea
countri
contrast
medic
profession
significantli
reduc
risk
mortal
factor
associ
higher
mortal
risk
describ
variou
studi
digest
symptom
prolong
delay
onset
symptom
admiss
hospit
smoke
low
blood
pressur
impair
ga
exchang
leukopenia
anemia
disturb
liver
kidney
function
use
mechan
ventil
prolong
stay
icu
korean
outbreak
independ
risk
factor
mortal
age
year
dyspnea
diabet
chronic
lung
diseas
systol
blood
pressur
admiss
mmhg
hyperleukocytosi
admiss
use
mechan
ventil
posit
pcr
result
merscov
blood
diagnosi
associ
increas
risk
requir
mechan
ventil
extracorpor
membran
oxygen
ecmo
lead
death
lack
delay
detect
mer
antibodi
elisa
igg
iga
prnt
blood
airway
poor
prognost
factor
howev
note
seroconvers
observ
asymptomat
mersinfect
patient
final
merscov
viral
load
distal
lung
sampl
higher
among
deceas
patient
studi
includ
patient
tertiari
referr
hospit
south
korea
predict
factor
pneumonia
merscov
patient
age
year
bodi
temperatur
c
day
platelet
count
lymphocytopenia
crp
mgl
high
viral
load
ct
valu
predict
factor
respiratori
failur
male
sex
high
blood
pressur
thrombocytopenia
lymphocytopenia
hypoalbuminemia
gl
crp
mgl
patient
least
two
one
none
predict
pneumonia
factor
develop
pneumonia
case
respect
sever
therapeut
option
target
variou
viral
element
current
avail
develop
fig
differ
class
avail
treatment
immunotherapi
specif
antimerscov
antibodi
ii
molecul
antivir
activ
iii
symptomat
treatment
molecul
shown
real
cur
action
report
literatur
gener
describ
isol
case
small
seri
case
studi
focus
associ
treatment
support
care
time
prevent
therapi
still
preclin
stage
efficaci
safeti
plasma
convalesc
patient
assess
three
separ
report
conclud
therapeut
approach
inappropri
one
trial
list
wwwclinicaltrialsgov
two
case
therapi
intraven
polyclon
igg
report
one
igg
origin
donor
region
neg
mer
specif
antibodi
sever
monoclon
antibodi
test
seem
show
antimerscov
activ
vitro
clinic
trial
current
underway
recent
phase
placebocontrol
dose
escal
studi
evalu
efficaci
polyclon
igg
produc
transchromosom
cattl
human
immunoglobulin
gene
immun
merscov
spike
protein
primari
outcom
toler
singl
dose
reach
secondari
pharmacodynam
endpoint
serum
neutral
activ
show
efficaci
dose
mgkg
phase
ii
trial
current
underway
phase
studi
regist
assess
immunogen
toler
combin
two
monoclon
antimerscov
antibodi
studi
yet
start
recruit
patient
infect
merscov
reduc
host
interferon
respons
merscov
time
sensit
treatment
report
mani
clinic
case
sever
retrospect
cohort
studi
perform
combin
ribavirin
lopinavir
mycophenol
mofetil
mmf
none
studi
demonstr
increas
overal
surviv
one
studi
report
increas
surviv
critic
ill
intub
ventil
patient
ifnmmf
combin
trial
current
underway
see
high
dose
ribavirin
shown
antimerscov
activ
vitro
ribavirin
use
treat
patient
saudi
arabia
well
franc
sever
case
manag
icu
signific
effect
demonstr
either
mortal
rate
time
spent
icu
ritonavirboost
lopinavir
shown
efficaci
merscov
vitro
result
fda
extend
indic
lopinavir
patient
infect
merscov
two
case
report
greec
korea
describ
improv
patient
treat
lopinavir
type
interferon
ribavirin
phase
iiiii
clinic
trial
regist
clinicaltrialsgov
aim
studi
evalu
feasibl
efficaci
safeti
combin
lopinavirritonavirrecombin
vs
placebo
patient
confirm
mer
receiv
optim
symptomat
care
chloroquin
among
molecul
approv
fda
follow
vitro
studi
clinic
data
studi
support
use
vivo
present
time
vitro
antimerscov
activ
demonstr
dose
nitazoxamid
could
reach
two
daili
oral
dose
clinic
data
studi
support
use
vivo
present
time
vitro
antimerscov
activ
demonstr
dose
mmf
accept
use
human
mmf
seem
show
synergist
effect
vitro
non
human
primat
common
marmoset
model
anim
treat
mmf
develop
sever
lesion
show
higher
case
fatal
rate
compar
untreat
anim
contrast
anim
model
combin
administ
patient
saudi
arabia
patient
surviv
lower
apach
ii
score
patient
group
alisporivir
shown
provid
addit
vitro
antimerscov
activ
use
combin
ribavirin
clinic
data
studi
support
use
vivo
present
time
silvestrol
molecul
flavaglin
famili
found
plant
bind
enhanc
affin
mrna
block
helicas
activ
inhibit
protein
translat
recent
vitro
studi
demonstr
silvestrol
antimerscov
activ
clinic
data
studi
support
use
vivo
present
time
corticosteroid
therapi
current
wide
studi
therapeut
option
retrospect
studi
arabi
et
al
compar
outcom
patient
confirm
merscov
infect
manag
icu
set
treat
without
corticosteroid
therapi
overal
fatal
rate
univari
analysi
show
mortal
icu
hospit
stay
day
higher
corticosteroid
group
follow
adjust
use
margin
structur
model
causal
infer
corticosteroid
therapi
shown
associ
mortal
delay
viru
clearanc
find
togeth
absenc
descript
advers
effect
caus
corticosteroid
treatment
argu
use
corticosteroid
retrospect
studi
recent
carri
saudi
arabia
merscov
patient
refractori
respiratori
failur
patient
includ
studi
five
icu
studi
consist
two
patient
group
ecmo
versu
convent
treatment
primari
endpoint
inhospit
mortal
secondari
endpoint
includ
length
stay
icu
hospit
thirtyf
patient
includ
treat
ecmo
receiv
convent
care
group
similar
baselin
characterist
inhospit
mortal
lower
ecmo
group
vs
p
although
stay
longer
icu
median
stay
day
vs
day
p
overal
time
hospit
similar
group
median
stay
vs
day
p
addit
patient
ecmo
group
show
improv
valu
day
admiss
icu
vs
vs
respect
p
lower
level
vasoact
amin
vs
vs
respect
p
result
studi
support
use
ecmo
salvag
treatment
mer
patient
respiratori
failur
case
respiratori
infect
two
trial
candid
vaccin
current
regist
http
phasei
clinic
trial
healthi
volunt
set
evalu
safeti
immunogen
plasmid
dna
vaccin
express
protein
merscov
trial
plan
last
one
year
start
result
avail
yet
second
phasei
trial
start
oxford
univers
januari
use
chimpanze
adenoviru
vector
contain
merscov
protein
gene
patient
inclus
current
underway
mani
candid
vaccin
use
variou
differ
technolog
less
advanc
stage
develop
mer
epidem
start
contrast
sarscov
disappear
year
first
appear
merscov
continu
persist
middl
east
year
later
although
diseas
becom
pandem
outbreak
occur
worldwid
today
imposs
predict
certainti
whether
merscov
disappear
continu
remain
threat
human
popul
effici
vaccin
develop
host
anim
human
could
play
key
role
tilt
balanc
potentiallypandem
merscov
elimin
furthermor
epidemiolog
viral
determin
emerg
merscov
middl
east
difficult
comprehend
due
high
seroposit
rate
african
dromedari
camel
similar
diseas
local
human
popul
constant
increas
transcontinent
travel
particular
toward
main
focal
point
mer
outbreak
religi
pilgrimag
mass
tourism
rais
problem
manag
patient
suspect
merscov
infect
absenc
effici
treatment
option
date
main
problem
nonepidem
countri
detect
merscov
case
among
great
number
nonmer
patient
franc
except
first
case
case
detect
current
strategi
isol
suspici
case
rapidli
possibl
contain
infect
prevent
local
outbreak
seen
south
korea
abil
rapidli
test
patient
suspect
merscov
infect
cornerston
strategi
experi
gain
last
year
health
commun
also
help
deal
respiratori
infect
emerg
futur
author
declar
compet
interest
